Press conference held to announce the commencement of an international trial for inherited Alzheimer's disease
A research group led by Professor Takeshi Ikeuchi, Assistant Professor Kensaku Kasuga (both from BRI Dept of Molecular Genetics) and Dr Yoshiki Niimi (Specially Appointed Associate Professor at the University of Tokyo) has launched the DIAN NexGen* global clinical trial for inherited Alzheimer's disease. This trial is named "A phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease." The trial will test the effects of a combination of anti-amyloid-β and anti-tau antibody drugs on biomarkers and cognitive function in individuals with a genetic mutation that causes inherited Alzheimer's disease.
A press conference was held on this matter on Thursday 14 March by the three aforementioned scientists.
The results of this trial are expected to accelerate the development of treatments for sporadic Alzheimer's disease, which affects a large number of patients, in addition to inherited Alzheimer's disease.
Media coverage
